Loading
companiesCompany
Shanghai Junshi Biosciences
Junshi developed toripalimab, the first Chinese PD-1 antibody approved in China (2018) and the first approved by the FDA (2023, nasopharyngeal cancer).
Also called: Junshi君实生物
Overview
Toripalimab (Tuoyi / Loqtorzi) has more than ten NMPA indications, US approval for nasopharyngeal carcinoma with Coherus (licence February 2021, $150 million upfront), and EU, UK and Australian approvals. Pipeline: the BTLA antibody tifcemalimab, a PD-1 x VEGF bispecific and ADCs. Junshi also co-developed the COVID-19 antibody etesevimab with Lilly.
Headquarters
Shanghai, CN
Scorecard
All companies#82of 1244 companies, score 56
- approved products +6
- phase 3 +3
- phase 1/2 +2
- targets +6
- modalities +4
- regions +5
- registry trials +30
1 approved, 1 in phase 3, 2 earlier, 3 targets, 626 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2021-02-01 | Shanghai Junshi Biosciences to Coherus BioSciences Toripalimab (Loqtorzi), anti-PD-1 antibody; options on two further programmes | Licence | $150m | up to $1.11bn | source |
Type
Biotech · 1877.HK / 688180.SS
Stage
Public
Website
Founded
2012
ApprovedMonoclonal antibody (anti-PD-1)
Toripalimab · Loqtorzi
A Chinese-developed PD-1 blocker that became the first immunotherapy approved in the US for nasopharyngeal cancer.
Phase 3small molecule (structure undisclosed or not yet in PubChem)
JS105 is an experimental small-molecule drug from Risen (Suzhou) Pharma Tech in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
ApprovedOral PARP inhibitor
Fluzoparib is an oral parp inhibitor from Risen (Suzhou) Pharma Tech Co., Ltd., in registered phase 2 trials for metastatic cancer.
Phase 2small molecule (structure undisclosed or not yet in PubChem)
JS111 is an experimental small-molecule drug from Suzhou Junjing BioSciences in phase 2 trials for non-small-cell lung cancer, aimed at EGFR and MET.
Similar pages
- TreatmentDalpiciclib
Shares A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors and the tag china.
- PersonJun Guo
Shares Toripalimab and the tag china.
- TrialRELIANCE
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag china.
- TrialORIENT-11
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag china.
- TreatmentRelmacabtagene autoleucel
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag china.
- InstitutionNational Healthcare Security Administration
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag china.
- CompanyInnovent Biologics
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag china.
- TreatmentSintilimab
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag china.
fronts
drugs
ApprovedOral PARP inhibitor
Phase 3small molecule (structure undisclosed or not yet in PubChem)
Phase 2small molecule (structure undisclosed or not yet in PubChem)
ApprovedMonoclonal antibody (anti-PD-1)
Toripalimab · Loqtorzi
trials
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid TumorsA Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal CancerA Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast CancerA Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic HepatJS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）JS207 Combination Therapy in Triple-negative Breast CancerJS212 Combination Therapies in Metastatic Colorectal CancerJUPITER-02JUPITER-06Neotorch